In general, adverse drug reactions (ADRs) experienced with 5-ARIs are dose-dependent.
The FDA has notified healthcare professionals that the Warnings and Precautions section of the labels for the 5-ARI class of drugs has been revised to include new safety information about the increased risk of being diagnosed with a more serious form of prostate cancer (high-grade prostate cancer) [REF].